| Literature DB >> 29911680 |
Yeonjeong Ha1, Saebom Ko1, Ijung Kim2, Yimin Huang1, Kishore Mohanty1, Chun Huh1, Jennifer A Maynard1.
Abstract
Superparamagnetic nanoparticles (SPMNPs) have attracted interest for various biomedical applications due to their unique magnetic behavior, excellent biocompatibility, easy surface modification, and low cost. Their unique magnetic properties, superparamagnetism, and magnetophoretic mobility have led to their inclusion in immunoassays to enhance biosensor sensitivity and allow for rapid detection of various analytes. In this review, we describe SPMNP characteristics valuable for incorporation into biosensors, including the use of SPMNPs to increase detection capabilities of surface plasmon resonance and giant magneto-resistive biosensors. The current status of SPMNP-based immunoassays to improve the sensitivity of rapid diagnostic tests is reviewed, and suggested strategies for the successful adoption of SPMNPs for immunoassays are presented.Entities:
Year: 2018 PMID: 29911680 PMCID: PMC5999228 DOI: 10.1021/acsanm.7b00025
Source DB: PubMed Journal: ACS Appl Nano Mater ISSN: 2574-0970
Figure 1Modification of SPMNPs for analyte detection. (a) For incorporation into immunoassays, SPMNPs can be covalently decorated with antibodies specific for a given analyte and concentrated using an external magnet. (b) This allows for capture of the analyte in a complex mixture, even when the analyte is present at dilute concentrations. (c) Direct visualization of Fe3O4 SPMNPs using transmission electron microscopy. SPMNPs have spherical shape and an average diameter of ∼10 nm and often form clusters or small aggregates with a size of ∼50 nm. The scale bar indicates 50 nm. (c) Reproduced with permission from Ko et al. (2017).[16]
SPR and GMR Sensors Based on Magnetic Nanoparticles
| sensor | SPMNP composition | NP size | analyte | detection limit | detection range | ref |
|---|---|---|---|---|---|---|
| SPR | streptavidin conjugated Fe2O3 magnetic nanoparticles | 50 nm | brain natriuretic peptide | ND | 0.025–1 ng/mL | ( |
| streptavidin conjugated superparamagnetic nanoparticles | 50 nm | Staphylococcal enterotoxin B | ND | 0.10–10 ng/mL | ( | |
| tosyl-activated superparamagnetic nanoparticles | 1 μm | prostate specific antigen | 10 fg/mL | 1 fg/mL–100 ng/mL | ( | |
| magnetic nanoparticles with iron oxide core | 220 ± 63 nm | beta human chorionic gonadotropin | 0.45 pM | ND | ( | |
| carboxyl group modified Fe3O4 magnetic nanoparticles | 10.5 nm | thrombin | 0.017 nM | 0.27–27 nM | ( | |
| core/shell Fe3O4/SiO2 nanoparticles | 16 nm | rabbit IgG | ND | 1.25–20 μg/mL | ( | |
| core/shell Fe3O4/Ag/SiO2 nanoparticles | 19 nm | rabbit IgG | ND | 0.30–20 μg/mL | ( | |
| core/shell Fe3O4/Au nanoparticles modified with 3-mercaptopropionic acid (MPA) | 8–30 nm | human IgM | ND | 0.30–20 μg/mL | ( | |
| Iron oxide carboxyl-modified magnetic nanoparticles | 200 nm | Ochratoxin A | 0.94 ng/mL | 1–50 ng/mL | ( | |
| core/shell Fe3O4/Au nanoparticles | 25–30 nm | A-fetoprotein | 0.65 ng/mL | 1.0–200.0 ng/mL | ( | |
| Fe3O4–Au nanorod (50 × 15 with 0.05 mmol/L AgNO3, 65 × 30 with 0.1 mmol/L AgNO3) | goat IgM | ND | 0.15–40.00 μg/mL | ( | ||
| Fe3O4/Ag/Au nanocomposite | 35 nm | Dog IgG | 0.15 μg/mL | 0.15–40.00 μg/mL | ( | |
| carboxyl group modified Fe3O4 magnetic nanoparticles | 6.53 ± 0.22 nm | 14 cfu/mL | 14–1.4 × 109 cfu/mL | ( | ||
| GMR | streptavidin conjugated superparamagnetic nanoparticles | 300 nm | parathyroid hormone | 10 pM | ND | ( |
| cubic FeCo nanoparticles | 12.8 ± 1.58 nm | Interleukin-6 | ND | 125 fM–41.5 pM | ( | |
| streptavidin conjugated Fe2O3 nanoparticles | 50 nm | Aflatoxin B1 | 50 pg/mL | 0.050–50 ng/mL | ( | |
| streptavidin conjugated microbeads | ND | allergen Ara h 1 | 7. 0 ng/mL | 7.0–>2000 ng/mL | ( | |
| streptavidin conjugated microbeads | ND | allergen Ara h 2 | 0.2 ng/mL | 0.2–>250 ng/mL | ( | |
| streptavidin conjugated microbeads | ND | allergen gliadin | 1.5 ng/mL | 1.5–4000 ng/mL | ( | |
| streptavidin conjugated cubic FeCo nanoparticles | 12.8 ± 1.58 nm | endoglin | 83 fM | ND | ( | |
| streptavidin conjugated superparamagnetic nanoparticles | 50 nm | Staphylococcal enterotoxin A | 0.1 ng/mL | ND | ( | |
| streptavidin conjugated superparamagnetic nanoparticles | 50 nm | toxic shock syndrome toxin | 0.3 ng/mL | ND | ( | |
| streptavidin conjugated magnetic nanoparticles | ND | Flt3 ligand | ND | 0.020–3 μg/mL | ( | |
| streptavidin conjugated magnetic nanoparticles | ND | serum amyloid A1 | ND | 3–50 ng/mL | ( | |
| streptavidin conjugated magnetic nanoparticles | ND | influenza A virus | 1.5 × 102 TCID | 1.5 × 102–1.0 × 105 TCID 50/mL | ( |
TCID, tissue culture infective dose.
Figure 2SPMNPs to enhance SPR sensitivity. (a) SPR devices typically function by immobilizing a capture antibody on a supported gold film. Polarized light is refracted by the gold film at an angle Θ1 greater than would be expected due to the mass of bound antigen affecting the surface plasmon resonance. If the antigen has a small mass, the angle is small and can be difficult to detect. (b) Detection sensitivity can be increased by detecting bound antigen with a second detection antibody, thereby increasing the amount of mass bound and the reflection angle Θ2 per bound antigen. (c) Sensitivity can be further increased by using a detection antibody bound to an SPMNP with a large total mass, resulting in a much larger angle Θ3 per antigen molecule bound, and thereby lowering the concentration of antigen that can be reliably detected.
Figure 3Spin-valve GMR sensor to detect analyte. (a) A test sensor is first functionalized with a capture antibody specific for the target analyte. This is used to capture analyte and create an immune sandwich culminating in SPMNPs. The magnetic signal from the immobilized SPMNPs enables quantification of the analyte concentration using a standard curve. A separate control sensor is coupled with bovine serum albumin (BSA) to detect background signal resulting from nonspecific binding. (b) The molecular assembly used for detection includes the capture antibody covalently coupled to the sensor surface that binds the target analyte. This is then detected by a second antibody binding a different epitope on the analyte. Since the detection antibody is biotinylated, it can in turn be bound by a streptavidin-conjugated SPMNP. This sensor was reported in Osterfeld et al.[60]
Figure 4Sample concentration using mixed a AuNP/SPMNP system for lateral flow immunoassays. (a) Polymer and antibody-coated AuNPs were combined with polymer-coated SPMNPs and human plasma spiked with malaria antigens. (b) Heating to 40 °C induced a polymer phase transition and coaggregation of the AuNPs and SPMNPs, which were collected using an external magnet. The supernatant was removed, and the particles were redispersed in a smaller volume of buffer. (c) The concentrated particles were directly applied to a standard lateral flow immunoassay and migrated down the paper strip by capillary action. The gold nanoparticles accumulated at the test and control lines, allowing for visual inspection of the results, while the SPMNPs were transported into the waste. Figure inspired by Nash et al.[22]
Comparison of SPMNPs Immunoassays and Conventional ELISA Limit of Detection
| analyte | ELISA LOD | sensor type | SPMNPs immunoassay LOD | ref |
|---|---|---|---|---|
| peanut Ara h 1 | 31.5 ng/mL | GMR | 7.0 ng/mL | ( |
| peanut Ara h 2 | 2 ng/mL | GMR | 0.2 ng/mL | ( |
| wheat gliadin | 40 ng/mL | GMR | 1.5 ng/mL | ( |
| Staphylococcal enterotoxins (SEs) | 0.1–0.5 ng/mL | magnetic particle quantification (MPQ) method | 0.3 ng/mL (express MIA) | ( |
| 10 pg/mL (HV MIA) | ||||
| prostate specific antigen (PSA) | ∼100 pg/mL | magnetic particle quantification (MPQ) method | 25 pg/mL | ( |
Copolymer-Coated Magnetic Nanoparticles
Figure 5Reusable SPMNP immunoassays. After analyte capture by both the antibody-coated SPMNPs, antigen-bound SPMNPs are concentrated at the sensor surface by a magnet for signal detection. These are then released by detaching the external magnet and removed by flowing buffer solution. New SPMNPs are easily attached on the sensor surface by attaching the external magnet and ready for a new assay.